28 October 2026 REPORT ON ACTIVITIES FOR THE QUARTER ENDED 30 SEPTEMBER 2026 Quarter Highlights: • Continued work with an international regulatory advisory group on an updated European Medicines Agency submission requesting advice on the European regulatory pathway and pivotal clinical trial...